top of page

AbTherx licenses Atlas antibody discovery platform to Athenova for targeted alpha cancer therapies

Writer: nuaxia
nuaxia
1 hour ago
2 min read

Athenova will use AbTherx's fully human antibody discovery technology for astatine-211 radiopharmaceutical programmes under a licensing agreement involving research payments, milestones and royalties.


On 18 November 2026, AbTherx announced a licensing agreement with Athenova Therapeutics giving the French biotechnology company access to its Atlas Full Human Diversity Mice platform to discover fully human antibodies for targeted alpha radiopharmaceutical development.


Athenova receives development and commercialisation rights to antibodies discovered under the licence in exchange for research payments, development milestones and royalties, with financial amounts undisclosed and therapeutic candidates still under development.

Field

Content

Alert Type

Deal

Companies

AbTherx; Athenova Therapeutics

Deal Type

Antibody discovery platform licensing agreement

Asset or Company

Atlas Full Human Diversity Mice platform; antibodies discovered for Athenova's targeted alpha radiopharmaceutical programmes

Therapy Area(s)

Oncology; targeted alpha radiopharmaceutical therapy

Technology or Modality

Fully human antibody discovery using transgenic Atlas mice; investigational astatine-211 targeted alpha radiopharmaceutical conjugates

Deal Value

Financial amounts not disclosed; consideration comprises research payments, development milestones and royalties on net sales.

Geography

United States and France; platform access supported through a European research partner

What Happened

AbTherx licensed access to its Atlas Full Human Diversity Mice technology to Athenova Therapeutics for the discovery of fully human antibodies intended for the company's astatine-211 radiopharmaceutical conjugate programmes.

Why It Matters

Targeted alpha radiopharmaceutical development requires suitable targeting molecules. The agreement gives Athenova access to an antibody discovery platform while retaining development and commercialisation rights to antibodies generated under the licence.

Supporting Context

Athenova is a France-based biotechnology company developing targeted alpha therapies using astatine-211. AbTherx provides transgenic mouse technology designed to generate diverse fully human therapeutic antibody candidates.

Strategic Rationale

Athenova gains access to specialised antibody discovery capabilities without developing its own transgenic mouse platform, while AbTherx expands its Atlas licensing activities into targeted radiopharmaceutical discovery.

Potential Impact

The collaboration could generate antibody candidates suitable for further development as targeted alpha radiopharmaceuticals, although successful candidate selection, clinical safety and therapeutic efficacy remain to be demonstrated.

Key Takeaway

AbTherx has licensed its Atlas platform to Athenova for investigational astatine-211 cancer therapy discovery under undisclosed financial terms involving research payments, milestones and royalties.

What to Watch

Identification of antibody leads, progress towards radiopharmaceutical development candidates, preclinical evaluation and subsequent clinical development plans.

Primary Source

https://www.abtherx.com/abtherx-licenses-atlas-platform-to-athenova-therapeutics-for-next-generation-targeted-alpha-radiopharmaceutical-discovery/

Relevant Date

18 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page